Scancell Holdings Reports Strong Phase 2 Data On iSCIB1+ In Melanoma
July 22 (Reuters) - Scancell Holdings PLC SCLP.L:
SCANCELL HOLDINGS PLC: STRONG PHASE 2 DATA ON ISCIB1+ IN MELANOMA
SCANCELL HOLDINGS PLC - ISCIB1+ SHOWS 69% RESPONSE RATE, EXCEEDS STANDARD CARE
Disclaimer: The information provided on this website is for educational and informational purposes only and should not be considered financial or investment advice.